Description: INVO Bioscience, Inc. is an innovative medical device company developing solutions for the global infertility industry. INVO's goal is to increase access to care and expand fertility treatment across the globe while seeking to lower the cost and increase the availability of care. INVO's lead commercial product, the INVOcell, is a patented Assisted Reproductive Technology (ART) used in the treatment of infertility. The INVOcell device and procedure is unique as the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development. As an alternative to traditional in Vitro Fertilization (IVF), the revolutionary in vivo method of vaginal incubation offers patients a more natural and intimate experience. INVO Bioscience is headquartered in Sarasota, FL.
Home Page: www.invobio.com
INVO Technical Analysis
5582 Broadcast Court
Sarasota,
FL
34240
United States
Phone:
978 878 9505
Officers
Name | Title |
---|---|
Mr. Steven M. Shum | CEO & Director |
Mr. Andrea Goren | Chief Financial Officer |
Mr. Michael Jos. Campbell | COO & VP of Bus. Devel. |
Dr. Kevin Doody M.D. | Medical Director & Director |
Mr. Bojan Mitrovic Ph.D. | Director of Sales US |
Dr. Barbara Levy F.A.C.S., FACOG, M.D. | Sr. VP of Global Clinical Integration |
Mr. Chris Myer | Sr. VP of Bus. Devel. of Americas |
Mr. Robert Joseph Bowdring Jr. | Treasurer & Sec. |
Ms. Terah Krigsvold | Controller |
Ms. Lori Marzilli-Kahler | VP of Global Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Health Care Equipment & Services |
GIC Industry: | Health Care Equipment & Supplies |
GIC Sub-Industry: | Health Care Equipment |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 5.6708 |
Price-to-Sales TTM: | 1.4563 |
IPO Date: | 2012-05-21 |
Fiscal Year End: | December |
Full Time Employees: | 10 |